Investigating the direct detection of sepsis causing bacteria from whole human blood.

该项目调查直接从人的全血中检测引起败血症的细菌感染的可行性。这一过程包括通过快速循环冷冻和煮沸来裂解细菌细胞，然后用实时聚合酶链式反应(Real-time PCR)检测释放的核酸。与目前使用的广谱抗生素治疗相比，这种新的方法将能够在怀疑败血症后的关键1小时内检测到细菌感染，从而导致更有针对性和更适当的抗生素使用。如果临床医生有数据概述存在哪些细菌，以及重要的是哪些抗生素可能最合适，那么英国每年超过15万例细菌性脓毒症病例的结果将得到极大改善，并降低可归因于这种疾病的每年4万人的死亡率。BGR已经证明，这项技术及其仪器QuRapID能够检测到埃博拉、寨卡和疟疾等血液传播疾病。该项目将测试受感染的血液，以找出该技术的好处是否可以应用于脓毒症，那里的细菌细胞数量比病毒疾病少得多。BGR将可以从感染患者的血液中获得血液，以便在小范围内与NHS医院使用的现有黄金标准方法进行比较。

The project investigates the feasibility of detecting bacterial infections, causing sepsis, directly from whole human blood. The process involves lysing the bacterial cells by rapid cyclical freezing and boiling followed by detection of the released nucleic acid by real-time PCR. This novel approach will enable detection of bacterial infection in the critical ,1hr period after sepsis is suspected, leading to more targeted and appropriate use of antibiotics in contrast to the broad-spectrum antibiotic treatment used currently. If the clinician has data outlining which bacteria are present and importantly which antibiotics are likely to be most suitable, then the outcome for the more than 150k annual UK cases of bacterial sepsis will be greatly improved and reduce the 40k annual mortalities attributable to this condition. BGR has demonstrated that the technique and it's instrumentation, the QuRapID, is able to detect blood borne diseases such as Ebola, Zika and Malaria. This project will test infected blood in order to find out if the benefits of the technique can be applied to sepsis, where the number of bacterial cells is much lower than in viral disease. BGR will have access to blood from infected patients to compare on a small scale to existing gold standard methods in use by an NHS hospital.